|
Physiomics PLC on Tuesday said it has secured a new contract with long-standing client Numab Therapeutics AG, a Swiss clinical stage biotech company focused on the development of multi-specific antibodies in immunology and oncology. Physiomics is an Oxfordshire, England-based mathematical modelling company that supports oncology drug development. It said the project would involve the application of modelling and simulation techniques to support the pre-clinical development of a multi-specific antibody. The antibody is designed to activate anti-tumour immune responses for the treatment of cancer. Physiomics did not on Tuesday disclose the value of the deal. ‘This new contract marks another step in our long-term collaboration with Numab Therapeutics, reinforcing our role as a trusted partner to provide specialist modelling support to inform critical stages of drug development. We are delighted to be working once again with the Numab team,’ said Chief Executive Officer Peter Sargent. The collaboration is part of the two companies’ previously established partnership in applying model informed drug development to address difficulties with mathematical modelling and simulation technique. Physiomics expects the newest contract to be completed within the next two months. Shares in Physiomics closed down 1.3% at 0.39 pence each in London on Tuesday. The stock is down 68% over the past year. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
